Table of Contents
Introduction
New York, NY – January 8, 2025 – Global Cell Dissociation Market size is expected to be worth around US$ 1141.2 Million by 2032 from US$ 382.7 Million in 2023, growing at a CAGR of 13.3% during the forecast period from 2024 to 2032. In 2022, North America led the market, achieving over 37.20% share with a revenue of US$ 125.6 Million.
Cell dissociation, also referred to as trypsinization, is a process that utilizes a proteolytic enzyme to break down proteins, enabling the detachment of adhered cells from the surface of a cell culture vessel. This step is essential for preparing cells for further use. Cell dissociation reagents are designed to perform proteolytic and collagenolytic activities, facilitating the separation of cell tissues and lines from the glass or plastic surfaces of containers. This process improves cell viability and isolation efficiency. The choice of a dissociation agent depends on various factors, including the type of tissue or cells and the age of the cells in the culture medium.
In recent developments, Century Therapeutics and Bristol Myers Squibb entered into a research collaboration and license agreement in September 2022 to develop and commercialize up to four iPSC-derived programs targeting solid tumors and hematologic malignancies. Additionally, the launch of innovative products has created new opportunities.
For example, in November 2021, LevitasBio introduced Optimized Tissue Dissociation Reagents, specifically designed for use in the LeviCell workflows. These tissue dissociation kits enable seamless handling across a broad spectrum of human and model tissue types, including heart, tumor, brain, liver, lung, and kidney.
Key Takeaways
- The cell dissociation market is projected to reach USD 1,141.2 million by 2032, growing from USD 337.8 million in 2022.
- The market is anticipated to grow at a CAGR of 13.3% from 2023 to 2032.
- North America led the market in 2022 with a 37.20% share, driven by government investments and increasing medical conditions.
- The enzymatic dissociation segment was the dominant product type in 2022.
- Tissue dissociation accounted for the largest revenue share among dissociation types in 2022, with a 57% share.
- By tissue type, the connective tissues segment held the largest market share in 2022.
- Pharmaceutical and biotechnology companies were the leading end-users, contributing 71.60% of the revenue by the end of 2022.
- Advancements in technology are key growth drivers for the market.
- The high cost of products remains a significant challenge for market growth.
- The Asia Pacific region is expected to witness rapid growth in the forecast period.
- In June 2022, Immuneel Therapeutics secured USD 15 million for research.
- The market growth is further supported by innovations and increasing demand in healthcare and research sectors.
How Artificial Intelligence (AI) is Changing the Cell Dissociation Market?
- Automating Cell Culture Processes: AI-powered automation systems optimize cell culture processes, including cell dissociation. These systems minimize human error, ensure consistency, and accelerate workflows, making cell dissociation more efficient and reproducible.
- Improving Cell Viability Analysis: AI algorithms are employed to analyze cell viability post-dissociation. By interpreting complex datasets and images, AI ensures accurate assessments, helping researchers refine dissociation techniques and improve outcomes.
- Customizing Protocols with Machine Learning: Machine learning models can analyze cell types and tissue characteristics to recommend the best dissociation reagents and protocols. This customization reduces trial-and-error processes, saving time and resources.
- Enhancing Tissue Engineering: AI aids in optimizing tissue dissociation techniques for regenerative medicine and tissue engineering applications. By predicting optimal conditions, AI enhances the viability and functionality of dissociated cells.
- Advancing High-Throughput Screening: AI integration in high-throughput systems enables rapid dissociation and analysis of large cell populations. This advancement is particularly useful in drug discovery and biomarker identification.
- Driving Predictive Maintenance for Equipment: AI systems monitor the performance of dissociation equipment and predict maintenance needs, reducing downtime and ensuring consistent results.
- Facilitating Data-Driven Research: AI tools analyze vast datasets from cell dissociation experiments, uncovering patterns and insights that help refine methods and advance understanding of cellular behavior.
Segmentation Analysis
- Product Analysis
- The market is segmented into enzymatic dissociation, non-enzymatic dissociation, and instruments & accessories.
- Enzymatic dissociation dominates the market, primarily driven by the collagenase segment.
- Collagenase Type 1 is commonly used for tissue dissociation in epithelial, liver, adipocyte, and adrenal tissues.
- Dissociation Analysis
- Segments include tissue dissociation and cell detachment.
- Tissue dissociation led in 2022, with a 57% revenue share, driven by biopharma’s focus on monoclonal antibodies and personalized medicine.
- Cell detachment is projected to grow fastest, supported by rising funding for cell culture advancements.
- Tissue Analysis
- Segmented into connective tissues, epithelial tissues, and others.
- Connective tissues dominated in 2022 due to their vital roles in supporting and shielding organs.
- Dissociation products are widely used to isolate cells like fibroblasts, adipocytes, and osteoblasts from connective tissues.
- End-User Analysis
- Segments include pharmaceutical companies, biotechnology companies, academic institutes, and research institutes.
- Pharmaceutical and biotechnology companies held over 71.60% revenue share in 2022 and are expected to maintain their dominance, driven by rapid advancements and strategic investments.
Key Player Analysis
- Merck KGaA (January 2024): Acquired Promega Corporation, aiming to enhance its cell dissociation portfolio by integrating Promega’s advanced enzymatic dissociation technologies. This acquisition is expected to improve the efficiency and reliability of cell culture processes.
- Thermo Fisher Scientific: (March 2024): Launched the Gibco TrypLE Express Enzyme, a recombinant enzyme designed to offer a safer and more efficient alternative to traditional trypsin, thus improving cell culture outcomes.
- Danaher Corp. (February 2024): Enhanced its cell dissociation capabilities by acquiring Cytiva, which is known for its cell processing technologies. This strategic move is aimed at bolstering Danaher’s biopharmaceutical manufacturing offerings.
- Stemcell Technologies (April 2024): Released the EasySep Releasable Cell Dissociation Kit. This product facilitates gentle and efficient cell dissociation, preserving cell viability and functionality, and is suited for downstream applications.
- Sartorius AG (March 2024): Acquired a majority stake in CellGenix, a provider of high-quality cell dissociation reagents. This acquisition is intended to enhance Sartorius’s offerings in the cell culture market and expand its global footprint.
- Miltenyi Biotec (January 2024): Announced a merger with SynGen Inc., aiming to merge SynGen’s innovative cell processing technologies with Miltenyi’s expertise in magnetic cell separation to boost their capabilities in cell dissociation and processing.
Emerging Trends
- Engineered Cell Therapies: Innovations such as engineered T cells for autoimmunity and in vivo CAR-T cell engineering are pushing the boundaries of cell dissociation technologies. These therapies require precise cell isolation techniques to ensure the efficacy and safety of the treatments.
- Nonviral Gene Delivery: Emerging technologies focus on nonviral methods for gene delivery, which necessitate the development of efficient cell dissociation techniques to prepare cells for these advanced therapies.
- Capsid Engineering: This involves the modification of virus capsids to enhance delivery efficiency to cells, requiring precise dissociation and isolation techniques to ensure targeted delivery and minimize off-target effects.
- iPSC-Derived Therapies: Induced pluripotent stem cell technologies are expanding, with cell dissociation playing a crucial role in the production and maintenance of iPSCs for therapeutic applications.
- Synthetic Biology: This field combines engineering principles with biology and is rapidly growing, relying on sophisticated cell dissociation methods to construct and deconstruct biological parts for research and therapeutic uses.
Use Case
- Research and Development: Cell dissociation is pivotal in scientific research, especially for understanding cellular functions and the impacts of diseases on cell biology. It allows for detailed analysis of isolated cells, crucial for studies on cellular responses to pharmacological treatments or genetic changes. This kind of research is fundamental in developing new treatments for diseases, including cancer and diabetes.
- Drug Testing and Toxicology: By isolating cells and exposing them to various compounds, researchers can observe how drugs affect cell health, behavior, and viability. This is essential in the early stages of drug development where the safety and efficacy of new therapeutic agents are assessed. Moreover, it supports toxicological studies, providing insights into compound toxicity at the cellular level.
- Cell-Based Therapy: Cell dissociation techniques are used to isolate and collect specific cell types for therapeutic purposes, such as regenerative medicine and transplantations. For example, isolating pancreatic islet cells for transplant into diabetic patients has shown potential in treating Type 1 Diabetes by restoring insulin production.
- Cancer Research: Dissociation of tumor cells from solid masses allows for the study of cancer cells in isolation, facilitating the investigation of their characteristics and responses to various treatments. This approach supports personalized medicine initiatives by enabling detailed analysis of tumor specifics and the efficacy of targeted therapy regimens.
- Diagnostic Applications: Isolated cells obtained through dissociation can be used in diagnostic applications, such as flow cytometry, where cells are analyzed individually to understand their properties, including size, shape, and marker expression. This technique is widely used in both clinical and research settings to diagnose diseases, monitor disease progression, and even guide treatment decisions.
Conclusion
The cell dissociation market is witnessing significant growth, driven by advancements in technology, increasing applications in research, and expanding therapeutic uses. Enzymatic dissociation leads the market, supported by innovations like AI-driven automation, high-throughput screening, and personalized protocols. Key players are enhancing their portfolios through strategic acquisitions and new product launches, addressing challenges like product costs and enhancing efficiency.
The Asia Pacific region is anticipated to experience rapid growth, while North America remains dominant due to strong investments. Emerging trends in cell therapies, synthetic biology, and nonviral gene delivery highlight the evolving demands in healthcare and biotechnology. With a projected CAGR of 13.3% from 2023 to 2032, the market remains integral to advancing diagnostics, drug discovery, and regenerative medicine.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
